

Hematology & Oncology Research Newsletter

Research Update for **the TPMG Hematology & Oncology Research Network!**

Spring 2024
Newsletter

Our newsletter presents current research projects led by TPMG clinicians, Division of Research (DOR) cancer division investigators and GME residents and fellows.

In this issue, we will provide you with updates regarding current research projects and a list of recent publications which demonstrate the breadth of our collective expertise and interests.

Of note, this newsletter does not include information about KPOCT (KP Oncology Clinical Trials), which supports our mission to provide highest quality care as a substantial contributor to the nation's National Clinical Trials Network and NCORP:

<https://wiki.kp.org/wiki/display/ncaloncology/Home>.



A Deeper Look Inside This Update:

- Researcher Highlight - new researchers join the Cancer Division, KP BREATHE
- Research Highlight - Cancer Screening Research Network
- Cancer Research Event Highlights
- Heme-onc clinical research activity, GME research activity
- Funding opportunities & Resources
- Recent publications

Researcher Highlights:

2024 is an eventful year with the announcement of a new Division of Research Cancer Section Director:



Congratulations to Dr. T.R. Levin for his appointment as the Associate Director for the DOR Cancer Section. The section has 13 research scientists and conducts research on a broad array of cancer types, evaluating cancer etiology, cancer care delivery, cancer screening, and outcomes research. Dr. Levin is a gastroenterologist in the Diablo Service Area and has worked at the DOR since 1995, when he joined as a research fellow. He is also the clinical lead for colorectal cancer screening for TPMG.

"I look forward to using my experience as a TPMG physician and DOR researcher to continue to build on the many successful TPMG and DOR collaborations that already exist and increase the impact that DOR research has on TPMG clinical care. "

Welcome to our two new medical oncology clinician-researchers who joined our Division of Research this year. They are working with our lung subspecialty team and DOR researcher Dr. Lori Sakoda to launch KP-BREATHE, a subspecialty research network to collectively move forward lung cancer research at TPMG-DOR:



Melisa Wong, MD, MAS, AGSF is a thoracic medical oncologist and geriatric oncology clinician-investigator. Her research program aims to transform cancer care for older adults. Dr. Wong is a National Institute on Aging Beeson K76 scholar having completed medical school and training in internal medicine, medical oncology, and advanced research training as an Aging Research Fellow at UCSF. She earned her Master's Degree in Clinical Research in the UCSF Department of Epidemiology and

Biostatistics. Nationally, Dr. Wong serves in a number of geriatric oncology leadership

positions including the American Society of Clinical Oncology Geriatric Oncology Community of Practice and Geriatric Oncology Education Committee, Cancer and Aging Research Group Health Services Core, and Editorial Board for the Journal of Geriatric Oncology.



Meera Ragavan, MD, MPH, is a thoracic oncologist whose research interests are centered around mitigating issues of access, affordability, and equity in cancer care delivery. Most recently, she secured a ASCO Young Investigator Award to study the impact of financial assistance programs on clinical outcomes for patients prescribed oral anti-cancer medications. She also serves as an editorial fellow for the Journal of Clinical Oncology-Oncology Practice. Dr. Ragavan earned her

undergraduate degrees in biology and economics at the University of Pennsylvania and went on to complete her medical degree and internal medicine residency at Stanford University before pursuing an oncology fellowship at the University of California, San Francisco, where she served as chief fellow. She additionally holds a Master's of Public Health with a focus in health policy from the Harvard T.H. Chan School of Public Health.

Research Highlight: Cancer Screening Research Network



Our cancer research spans from screening to survivorship, and there is big news this quarter about our screening program! Led by Dr. Jeffrey Lee (Gastroenterology, KP-SFO), we are part of the new [Cancer Screening Research Network](#) (CSRN) which will support the Biden-Harris Administration's [Cancer Moonshot](#)SM by investigating how to identify cancers earlier, when they may be easier to treat. KPNC will serve as one of 7 funded CSRN hubs that will lead efforts to enroll participants in their geographic

and coverage areas. In addition, as part of the CSRN, KPNC members will have access to novel screening technologies and clinical trials, which will inform the future of cancer screening and prevention.

Cancer Research Events

On November 10th 2023, the Division of Research hosted the first ever joint TPMG - DOR Cancer Division Cancer Research Symposium. Researchers from both TPMG and DOR presented their work in cancer care, and CEO Maria Ansari and Federation Cancer Excellence lead Tatjana Kolevska discussed their goals for cancer care and cancer research.



Upcoming Cancer Research Events

ASCO Annual Meeting:

ASCO Quality 2024

AACR Annual Meeting

ESMO

Each of our 11 major oncologic subspecialties have their own subspecialty meetings. Please contact your subspecialty research lead to learn more:

Breast oncology: Dr. Brandy Box-noriega

CNS: Dr. Scott Peak

Genomic oncology: Dr. Sachdev Thomas

GI: Dr. Tilak Sundaresan

GU oncology: Dr. Andrea Harzstark

Gyn-Oncology: Dr. Juraj Kavecansky

Head and Neck Cancer: Dr. Jed Katzel

Lung Cancer: Dr. Marie Suga

Malignant Hematology: Dr. Lisa Law

Melanoma: Dr. Tatjana Kolevska

Sarcoma: Dr. Jeanette Yu

Annual KP national cancer excellence symposium

Dates: Completed 3/8/24-3/9/24

Location: Hybrid

For more information: TBD for 2025 event

KP Oakland Research Symposium

Dates: May 17, 2024 12-2

Location: Hybrid

For more information: Todd.a.seigel@kp.org

KP San Francisco Research Symposium

Dates: May 22, 2024 12:30 - 1:30 PM

Location: Virtual

For more information: Tara.Greenhow@kp.org

TPMG-led Active Grant Funded Projects

The following is a list of active funded research projects being led or co-led by medical oncology at TPMG in 2024.



Dr. Lisa Law (KP-Roseville): Improving Adult Immunization Rates for COVID-19, Influenza and Routine Adult Vaccination through Partnerships with Medical Subspecialty Professionals



Dr. Tilak Sundaresan (KP-SFO): Understanding changes in body-composition prior to the development of pancreatic cancer



Dr. Jahan Tavakoli (KP-SFO): Real World Treatment Patterns and Outcomes in CLL/SLL Patients Receiving First and Second Generation Bruton Tyrosine Kinase Inhibitors (BTKi)



Dr. Jeffrey Velotta (KP-Oakland): Achieving guideline-concordant and equitable post-surgery biomarker testing and systemic therapy for patients with non-metastatic lung cancer using the 4R Oncology model



Dr. Raymond Liu (KP-SFO):

- 1) Adherence to Extended Endocrine Therapy in Early-Stage Breast Cancer Patients within an Integrated Health System.
- 2) Patient Characteristics Associated with Oncotype DX in an Integrated Health System
- 3) Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults with Cancer
- 4) Cancer outcomes with KPNC vs. National Community Averages: An Overview Study

GME Funded Projects

Thank you to all of our hematology-oncology mentors guiding our residents and fellows through projects. Our GME is having a breakthrough in accomplishments which include abstracts, posters, oral presentations, awards, and publications!

Here are some prominent highlights of recent work:

Gyn resident Bethany Waites publication in JNCCN has the potential to change NCCN surveillance guidelines for DCIS breast cancer patients: [Mammography and self exam best for detecting second breast cancer in women treated for DCIS - Kaiser Permanente Division of Research](#)

IM resident Dr. Brandon Anderson oral presentation at ASCO 2023 highlight the large number of secure messages that medical oncologists are managing: [Secure messaging increases oncologists' workload, leads to high volume of unreimbursed care \(healio.com\)](#)

Hematology-Oncology fellow Dr. Ashley Aller's publication on documentation of goals of care to improve goal concordant care in cancer patients: [Improving care for patients with advanced cancer - Kaiser Permanente Division of Research](#)



Welcome Shiyun Zhu to the DOR RAPT program and thank you to the RAPT program for helping our GME residents and fellows engage in hematology-oncology research!

Congratulations to our internal medicine residents, who are joining our hematology-oncology fellowship in July 2024:



Dr. Andrew Lynch, IM resident Kaiser Permanente Oakland, Research interest: Palliative care



Dr. Jenny Wei, IM resident Kaiser Permanente San Francisco, Research Interest: 4R, Onco-ED

Internal Funding & Research Resources

The **CURE fund (Cancer United Research Endeavor)** was created in 2021 for donations to be made to support TPMG cancer research (no solicitation allowed). Please contact Dr. Raymond Liu (Raymond.Liu@kp.org) if you have someone that has approached you to request a donation to support hematology-oncology.

If you need help with a project or idea, check in with your subspecialty or special topic research lead, or contact Dr. Raymond Liu (Raymond.Liu@kp.org).



General Funding Opportunities



Delivery Science and Applied Research



Specialty Research Networks



Getting Started with Research



Division of Research

Recent Peer Reviewed Publications authored by Heme-Onc Investigators (alphabetical)

Benign Hematology

1. Fang MC, Reynolds K, Tabada GH, Prasad PA, Sung SH, Parks AL, Garcia E, Portugal C, Fan D, Pai AP, Go AS. Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19. JAMA Netw Open. 2023 Mar 1;6(3):e232338. doi: 10.1001/jamanetworkopen.2023.2338. PMID: 36912838; PMCID: PMC10011935.
2. Roubinian NH, Vinson DR, Pai AP, Myers LC, Skarbinski J, Lee C, Mark DG, Liu VX. Risk of VTE in Nonrespiratory and Respiratory Presentations of COVID-19 in Critically Ill Patients. Chest. 2023 Jul;164(1):215-218. doi: 10.1016/j.chest.2023.02.008. Epub 2023 Feb 12. PMID: 36787875; PMCID: PMC9922435.
3. Yavorkovsky LL, Biller JA, Wallace KL. Pulmonary Arteriovenous Malformation (With Secondary Erythrocytosis): A Diagnosis Hastened by COVID-19 Pandemic. Mayo Clin Proc. 2023 Mar;98(3):443-444. doi: 10.1016/j.mayocp.2022.10.020. PMID: 36868751.

Breast Cancer

1. Hsu DS, Jiang SF, Habel LA, Hoodfar E, Karlea A, Manace-Brenman L, Dzubnar JM, Shim VC. Germline Genetic Testing Among Women ≤ 45 Years of Age with Ductal Carcinoma In Situ Versus Invasive Breast Cancer in a Large Integrated Health Care System. Ann Surg Oncol. 2023 Oct;30(11):6454-6461. doi: 10.1245/s10434-023-13745-4. Epub 2023 Jun 29. PMID: 37386303.
2. Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JA, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol. 2023 Oct;34(10):885-898. doi: 10.1016/j.annonc.2023.08.003. Epub 2023 Aug 18. PMID: 37597578.
3. Kantor ED, O'Connell K, Ergas IJ, Valice E, Roh JM, Bhimani J, Heon N, Griggs JJ, Lee J, Bowles EJ, Rivera DR, Kolevska T, Bandera EV, Kushi LH. Assessment of breast cancer chemotherapy dose reduction in an integrated healthcare delivery system. Breast Cancer Res Treat. 2024 Feb;203(3):565-574. doi: 10.1007/s10549-023-07126-4. Epub 2023 Nov 4. PMID: 37923962; PMCID: PMC10885738.
4. Kroenke CH, Kurtovich E, Aoki R, Shim VC, Chan TD, Brenman LM, Bethard-Tracy J, Adams AS, Kennedy DP. Evaluation of approaches to recruitment of racially and ethnically diverse breast cancer patients from an integrated health care setting for collection of observational social network data. Cancer Causes Control. 2023 Aug;34(8):705-713. doi: 10.1007/s10552-023-01709-8. Epub 2023 May 5. PMID: 37147410; PMCID: PMC10162650.
5. Kwan ML, Valice E, Ergas IJ, Roh JM, Caan BJ, Cespedes Feliciano EM, Kolevska T, Hartman TJ, Quesenberry CP Jr, Ambrosone CB, Kushi LH. Alcohol consumption and prognosis and survival in breast cancer survivors: The Pathways Study. Cancer. 2023 Dec 15;129(24):3938-3951. doi: 10.1002/cncr.34972. Epub 2023 Aug 9. PMID: 37555890; PMCID: PMC10840903.
6. Ossowski S, Lyon L, Linehan E, Gordon NP, Egorova O, Mark B, Beringer K, Abbe T, Shirazi A, Weldon C, Trosman J, Ravelo A, Liu R. Advance Directives for Patients With Breast Cancer: Applying the Right Info/Right Care/Right Patient/Right Time Oncology Model. Perm J. 2023 Sep 15;27(3):30-36. doi: 10.7812/TPP/22.177. Epub 2023 Jun 16. PMID: 37255340; PMCID: PMC10502389.

7. Rastogi P, Tang G, Hassan S, Geyer CE Jr, Azar CA, Magrinat GC, Suga JM, Bear HD, Baez-Diaz L, Sarwar S, Boileau JF, Brufsky AM, Shibata HR, Bandos H, Paik S, Yothers G, Swain SM, Mamounas EP, Wolmark N. Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. *Breast Cancer Res Treat.* 2023 Jun;199(2):243-252. doi: 10.1007/s10549-023-06881-8. Epub 2023 Mar 22. PMID: 36944848.
8. Shim VC, Baker RJ, Jing W, Puentes R, Agersborg SS, Lee TK, Goreal W, Achacoso N, Lee C, Villasenor M, Lin A, Kapali M, Habel LA. Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system. *Breast Cancer Res Treat.* 2024 Jan;203(2):281-289. doi: 10.1007/s10549-023-07118-4. Epub 2023 Oct 17. PMID: 37847456; PMCID: PMC10787679.
9. Vuong B, Darbinian J, Savitz A, Odele P, Perry LM, Sandhu L, Habel LA, Kuehner G. Breast Cancer Recurrence by Subtype in a Diverse, Contemporary Cohort of Young Women. *J Am Coll Surg.* 2023 Jul 1;237(1):13-23. doi: 10.1097/XCS.0000000000000714. Epub 2023 Apr 13. PMID: 37052317.
10. Waites BT, Lyon L, Kuehner G, Odele P, Habel LA, Liu R. Mode of Detection of Second Breast Cancers in Patients Undergoing Surveillance After Treatment of Ductal Carcinoma in Situ. *J Natl Compr Canc Netw.* 2023 Dec 28;22(1):e237082. doi: 10.6004/jnccn.2023.7082. PMID: 38154251.

Care Delivery

1. Cao C, Patel AV, Liu R, Cao Y, Friedenreich CM, Yang L. Trends and cancer-specific patterns of physical activity, sleep duration, and daily sitting time among US cancer survivors, 1997-2018. *J Natl Cancer Inst.* 2023 Dec 6;115(12):1563-1575. doi: 10.1093/jnci/djad146. PMID: 37527029; PMCID: PMC10699842.
2. Cao C, Wang N, Liu R, Patel AV, Friedenreich CM, Yang L. Leisure-time physical activity, daily sitting time, and mortality among US skin cancer survivors. *Support Care Cancer.* 2023 Nov 24;31(12):718. doi: 10.1007/s00520-023-08192-6. PMID: 37999788.
3. Hlubocky FJ, McFarland DC, Back AL, Friese CR, Lyckholm L, Gallagher CM, McGinnis M, Spence R, Lynch L, Tomkins J, Shanafelt T, Srivastava P. Development, Feasibility, and Acceptability of an Oncologist Group Peer Support Program From ASCO's Clinician Well-Being Task Force. *JCO Oncol Pract.* 2023 Aug;19(8):669-675. doi: 10.1200/OP.23.00068. Epub 2023 Jun 16. PMID: 37327462.
4. Kumar D, Gordon N, Zamani C, Sheehan T, Martin E, Egorova O, Payne J, Kolevska T, Neeman E, Liu R. Cancer Patients' Preferences and Perceptions of Advantages and Disadvantages of Telehealth Visits During the COVID-19 Pandemic. *JCO Clin Cancer Inform.* 2023 Sep;7:e2300040. doi: 10.1200/CCI.23.00040. PMID: 37656925; PMCID: PMC10569768.
5. Qian Y, Eppley S, Baer D, Melles RB. Characteristics of Ocular Inflammatory Side Effects Associated with Immune Checkpoint Inhibitors in a Northern California Population. *Ocul Immunol Inflamm.* 2024 Jan;32(1):98-104. doi: 10.1080/09273948.2022.2159447. Epub 2023 Jan 13. PMID: 36637986.
6. Tupper HI, Banks KC, Velotta JB. Are Food Deserts Just a Proxy for Socioeconomic Status? *Ann Thorac Surg.* 2023 Aug;116(2):253-254. doi: 10.1016/j.athoracsur.2023.04.039. Epub 2023 May 12. PMID: 37178861.

HNS

1. Katzel JA, Van Den Eeden SK, Liu R, Leimpeter A, Briones CB, Lewis DL, Lee-Enriquez NM, Patel M, Patel D, Gillis A, Yan J, Kaufman MA, Altschuler A, Shan J, Basch E. Real-World Use of Electronic Patient-Reported Outcome (ePRO) Tools Integrated in the Electronic Medical Record During Radiation Therapy for Head and Neck Cancer: Feasibility Study. *Perm J.* 2023 Sep 15;27(3):60-67. doi: 10.7812/TPP/23.046. Epub 2023 Aug 28. PMID: 37635460; PMCID: PMC10502391.

Genomics & Basic Science

1. Bulen BJ, Khazanov NA, Hovelson DH, Lamb LE, Matrana M, Burkard ME, Yang ES, Edenfield WJ, Claire Dees E, Onitilo AA, Buchschacher GL, Miller AM, Parsons BM, Wassenaar TR, Suga JM, Siegel RD, Irvin W, Nair S, Slim JN, Misleh J, Khatri J, Masters GA, Thomas S, Safa MM, Anderson DM, Mowers J, Dusenbery AC, Drewery S, Plouffe K, Reeder T, Vakil H, Patrias L, Falzetta A, Hamilton R, Kwiatkowski K, Johnson DB, Rhodes DR, Tomlins SA. Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit. *Cancer Res Commun*. 2023 Jul 25;3(7):1335-1349. doi: 10.1158/2767-9764.CRC-23-0036. PMID: 37497337; PMCID: PMC10367935.
2. Liu Z, Zhang Y, Ma N, Yang Y, Ma Y, Wang F, Wang Y, Wei J, Chen H, Tartarone A, Velotta JB, Dayyani F, Gabriel E, Wakefield CJ, Kidane B, Carbonelli C, Long L, Liu Z, Su J, Li Z. Progenitor-like exhausted SPRY1⁺CD8⁺ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. *Cancer Cell*. 2023 Nov 13;41(11):1852-1870.e9. doi: 10.1016/j.ccell.2023.09.011. Epub 2023 Oct 12. PMID: 37832554.
3. Pan M, Jiang C, Zhang Z, Achacoso N, Alexeeff S, Solorzano AV, Tse P, Chung E, Sundaresan T, Suga JM, Thomas S, Habel LA. *TP53* Gain-of-Function and Non-Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma. *JCO Precis Oncol*. 2023 May;7:e2200570. doi: 10.1200/PO.22.00570. PMID: 37163715.
4. Pan M, Jiang C, Zhang Z, Achacoso N, Solorzano-Pinto AV, Tse P, Chung E, Suga JM, Thomas S, Habel LA. Sex- and Co-Mutation-Dependent Prognosis in Patients with SMARCA4-Mutated Malignancies. *Cancers (Basel)*. 2023 May 9;15(10):2665. doi: 10.3390/cancers15102665. PMID: 37345003; PMCID: PMC10216441.
5. Tomlins SA, Khazanov NA, Bulen BJ, Hovelson DH, Shreve MJ, Lamb LE, Matrana MR, Burkard ME, Yang ES, Edenfield WJ, Dees EC, Onitilo AA, Thompson M, Buchschacher GL Jr, Miller AM, Menter A, Parsons B, Wassenaar T, Hwang LC, Suga JM, Siegel R, Irvin W Jr, Nair S, Slim JN, Misleh J, Khatri J, Masters G, Thomas S, Safa M, Anderson DM, Kwiatkowski K, Mitchell K, Hu-Seliger T, Drewery S, Fischer A, Plouffe K, Czuprenski E, Hipp J, Reeder T, Vakil H, Johnson DB, Rhodes DR. Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. *Commun Med (Lond)*. 2023 Feb 7;3(1):14. doi: 10.1038/s43856-023-00243-7. PMID: 36750617; PMCID: PMC9905474.

GI

1. Babic A, Rosenthal MH, Sundaresan TK, Khalaf N, Lee V, Brais LK, Loftus M, Caplan L, Denning S, Gurung A, Harrod J, Schawkat K, Yuan C, Wang QL, Lee AA, Biller LH, Yurgelun MB, Ng K, Nowak JA, Aguirre AJ, Bhatia SN, Vander Heiden MG, Van Den Eeden SK, Caan BJ, Wolpin BM. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. *Nat Commun*. 2023 Jul 18;14(1):4317. doi: 10.1038/s41467-023-40024-3. PMID: 37463915; PMCID: PMC10354105.
2. Kwak HV, Banks KC, Hung YY, Alcasid NJ, Susai CJ, Patel A, Ashiku S, Velotta JB. Adjuvant Immunotherapy in Curative Intent Esophageal Cancer Resection Patients: Real-World Experience within an Integrated Health System. *Cancers (Basel)*. 2023 Nov 7;15(22):5317. doi: 10.3390/cancers15225317. PMID: 38001577; PMCID: PMC10669669.
3. Kwak HV, Dzubnar JM, Hsu DS, Chang AL, Spitzer AL, Kazantsev GB, Peng PD, Chang CK. Survival of Elderly Patients Undergoing Pancreatoduodenectomy in an Integrated Health System. *J Surg Res*. 2023 Aug;288:315-320. doi: 10.1016/j.jss.2023.03.020. Epub 2023 Apr 12. PMID: 37058988.
4. Pham C, Niu F, Delate T, Buchschacher GL Jr, Li Y, Ekinci E, Le K, Hui RL. Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic

GU

1. Bai J, Pugh SL, Eldridge R, Yeager KA, Zhang Q, Lee WR, Shah AB, Dayes IS, D'Souza DP, Michalski JM, Efstathiou JA, Longo JM, Pisansky TM, Maier JM, Faria SL, Desai AB, Seaward SA, Sandler HM, Cooley ME, Bruner DW. Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415. *Int J Radiat Oncol Biol Phys*. 2023 May 1;116(1):39-49. doi: 10.1016/j.ijrobp.2023.01.035. Epub 2023 Feb 2. PMID: 36736921; PMCID: PMC10106367.
2. Krauss DJ, Karrison T, Martinez AA, Morton G, Yan D, Bruner DW, Movsas B, Elshaikh M, Citrin D, Hershatter B, Michalski JM, Efstathiou JA, Currey A, Kavadi VS, Cury FL, Lock M, Raben A, Seaward SA, El-Gayed A, Rodgers JP, Sandler HM. Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial. *J Clin Oncol*. 2023 Jun 10;41(17):3203-3216. doi: 10.1200/JCO.22.02390. Epub 2023 Apr 27. PMID: 37104748; PMCID: PMC10489479.
3. Presti J Jr, Alexeeff S, Avins AL. Screening for Prostate Cancer. *N Engl J Med*. 2023 Jul 6;389(1):93-94. doi: 10.1056/NEJMc2305651. PMID: 37407016.

GYN-ONC

1. Amin SA, Collin LJ, Kavecansky J, Setoguchi S, Satagopan JM, Bandera EV. Sociodemographic disparities in targeted therapy in ovarian cancer in a national sample. *Front Oncol*. 2023 May 12;13:1104630. doi: 10.3389/fonc.2023.1104630. PMID: 37251932; PMCID: PMC10213306.
2. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. *N Engl J Med*. 2023 Jun 8;388(23):2159-2170. doi: 10.1056/NEJMoa2302312. Epub 2023 Mar 27. PMID: 36972022; PMCID: PMC10351614.
3. Gomez SL, Chirikova E, McGuire V, Collin LJ, Dempsey L, Inamdar PP, Lawson-Michod K, Peters ES, Kushi LH, Kavecansky J, Shariff-Marco S, Peres LC, Terry P, Bandera EV, Schildkraut JM, Doherty JA, Lawson A. Role of neighborhood context in ovarian cancer survival disparities: current research and future directions. *Am J Obstet Gynecol*. 2023 Oct;229(4):366-376.e8. doi: 10.1016/j.ajog.2023.04.026. Epub 2023 Apr 26. PMID: 37116824; PMCID: PMC10538437.
4. Holloway RW, Mendivil AA, Kendrick JE, Abaid LN, Brown JV, LeBlanc J, McKenzie ND, Mori KM, Ahmad S. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. *JAMA Oncol*. 2023 Jul 1;9(7):903-908. doi: 10.1001/jamaoncol.2023.1007. PMID: 37227734; PMCID: PMC10214174.
5. Konski A, Deshmukh S, Klopp AH, Yeung AR, Westin SN, Thompson JS, Doncals DE, Cantuaria GHC, D'Souza DP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Patient Reported Outcome study of NRG oncology's RTOG 1203. *Gynecol Oncol*. 2023 Aug;175:176-181. doi: 10.1016/j.ygyno.2023.05.074. Epub 2023 Jun 30. PMID: 37393743; PMCID: PMC10527270.

6. Landen CN, Molinero L, Hamidi H, Sehouli J, Miller A, Moore KN, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian C, Thaker PH, Blank SV, Khor VK, Chang CW, Lin YG, Pignata S. Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. *Clin Cancer Res*. 2023 May 1;29(9):1698-1707. doi: 10.1158/1078-0432.CCR-22-2032. PMID: 36595569; PMCID: PMC10150250.
7. Muya S, Ndumbalo J, Kutika Nyagabona S, Yusuf S, Rhee DJ, Mushi BP, Li B, Zhang L, Grover S, Feng M, Hsu IC, Mmbaga E, Van Loon K, Court L, Xu M. Feasibility and Clinical Acceptability of Automation-Assisted 3D Conformal Radiotherapy Planning for Patients With Cervical Cancer in a Resource-Constrained Setting. *JCO Glob Oncol*. 2023 Sep;9:e2300050. doi: 10.1200/GO.23.00050. PMID: 37725767; PMCID: PMC10581615.
8. Pignata S, Bookman M, Sehouli J, Miller A, Penson RT, Taskiran C, Anderson C, Hietanen S, Myers T, Madry R, Willmott L, Lortholary A, Thomes-Pepin J, Aghajanian C, McCourt C, Stuckey A, Wu X, Nishio S, Copeland LJ, He Y, Molinero L, Patel S, Lin YG, Khor VK, Moore KN. Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer. *Gynecol Oncol*. 2023 Oct;177:20-31. doi: 10.1016/j.ygyno.2023.06.018. Epub 2023 Aug 23. PMID: 37625235.
9. Praiss AM, Miller A, Smith J, Lichtman SM, Bookman M, Aghajanian C, Sabbatini P, Backes F, Cohn DE, Argenta P, Friedlander M, Goodheart MJ, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray H, Secord AA, Van Le L, O'Cearbhaill RE. Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study. *Gynecol Oncol*. 2023 Jul;174:213-223. doi: 10.1016/j.ygyno.2023.05.013. Epub 2023 May 23. PMID: 37229879; PMCID: PMC10330633.
10. Sia TY, Tew WP, Purdy C, Chi DS, Menzin AW, Lovecchio JL, Bookman MA, Cohn DE, Teoh DG, Friedlander M, Bender D, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray HJ, Secord AA, Van Le L, Lichtman SM. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study. *Gynecol Oncol*. 2023 Jun;173:130-137. doi: 10.1016/j.ygyno.2023.03.018. Epub 2023 May 4. PMID: 37148580; PMCID: PMC10414765.
11. Strachowski LM, Jha P, Phillips CH, Blanchette Porter MM, Froyman W, Glanc P, Guo Y, Patel MD, Reinhold C, Suh-Burgmann EJ, Timmerman D, Andreotti RF. O-RADS US v2022: An Update from the American College of Radiology's Ovarian-Adnexal Reporting and Data System US Committee. *Radiology*. 2023 Sep;308(3):e230685. doi: 10.1148/radiol.230685. PMID: 37698472.

Lung

4. Kwak HV, Banks KC, Hung YY, Brennan PG, Wilde SA, Sumner ET, Sun A, Hsu DS, Velotta JB. Utilization and Outcomes of Observation for Spontaneous Pneumothorax at an Integrated Health System. *J Surg Res*. 2023 Aug;288:28-37. doi: 10.1016/j.jss.2023.02.031. Epub 2023 Mar 20. PMID: 36948030.
5. Jirasirinuphan P, Chang AL, Deepak A, Chang CK. Delayed metastatic pulmonary epithelioid hemangioendothelioma of the femoral vessels: case report and literature review. *AME Case Rep*. 2023 Jan 16;7:1. doi: 10.21037/acr-22-57. PMID: 36817709; PMCID: PMC9929661.
6. Alcasid NJ, Banks KC, Sun A, Velotta JB. Case report on the role of aggressive palliative surgery in lung NUT carcinoma after induction chemoimmunotherapy. *Int J Surg Case Rep*. 2023 Apr;105:108015. doi: 10.1016/j.ijscr.2023.108015. Epub 2023 Mar 21. PMID: 36948057; PMCID: PMC10040693.
7. Susai CJ, Velotta JB, Sakoda LC. Clinical Adjuncts to Lung Cancer Screening: A Narrative Review. *Thorac Surg Clin*. 2023 Nov;33(4):421-432. doi: 10.1016/j.thorsurg.2023.03.002. Epub 2023 May 12. PMID: 37806744; PMCID: PMC10926946.

8. Tupper HI, Velotta JB. Expanding clinicians' armamentarium for regional pain control after thoracic surgery. *J Thorac Dis.* 2023 May 30;15(5):2359-2362. doi: 10.21037/jtd-23-344. Epub 2023 May 17. PMID: 37324092; PMCID: PMC10267911.
9. Alcasid NJ, Velotta JB. The significance of digital drainage devices on standardization of air leak management after pulmonary resection. *J Thorac Dis.* 2023 Oct 31;15(10):5291-5293. doi: 10.21037/jtd-23-1331. Epub 2023 Sep 22. PMID: 37969300; PMCID: PMC10636457.
10. Ramesh N, Velotta JB. Pneumonectomy in an elderly patient with congenital unilateral lung hypoplasia and recurrent *Aspergillus*: a case report. *AME Case Rep.* 2022 Nov 4;7:9. doi: 10.21037/acr-22-38. PMID: 36817703; PMCID: PMC9929657.
11. Banks KC, Velotta JB. Pure Ground-Glass Opacities: Potential for Surgical Cure in Adenocarcinoma; However Selection Is Key. *Ann Thorac Surg.* 2023 Aug;116(2):237-238. doi: 10.1016/j.athoracsur.2023.01.034. Epub 2023 Feb 4. PMID: 36746326.
12. Alcasid NJ, Velotta JB. Challenges in Discovering the Optimal Anastomotic Approach to Improve Quality of Life in Minimally Invasive Esophagectomy (MIE). *Ann Thorac Surg.* 2023 Aug 24:S0003-4975(23)00903-7. doi: 10.1016/j.athoracsur.2023.08.005. Epub ahead of print. PMID: 37633583.
13. Alcasid NJ, Banks KC, Velotta JB. The impact of novel instrumentation in promoting uniportal video-assisted thoracoscopic surgery. *J Thorac Dis.* 2023 Aug 31;15(8):4143-4145. doi: 10.21037/jtd-23-814. Epub 2023 Jul 25. PMID: 37691676; PMCID: PMC10482622.
14. Alcasid NJ, Banks KC, Velotta JB. A Deeper Look at Dilations After Minimally Invasive Esophagectomy. *Ann Thorac Surg.* 2023 Oct;116(4):719-720. doi: 10.1016/j.athoracsur.2023.06.009. Epub 2023 Jun 30. PMID: 37393980.
15. Banks KC, Dusendang JR, Schmittiel JA, Hsu DS, Ashiku SK, Patel AR, Sakoda LC, Velotta JB. Association of Surgical Timing with Outcomes in Early Stage Lung Cancer. *World J Surg.* 2023 May;47(5):1323-1332. doi: 10.1007/s00268-023-06913-w. Epub 2023 Jan 25. PMID: 36695837; PMCID: PMC10070299.
16. Sakoda LC, Alabaster A, Sumner ET, Gordon NP, Quesenberry CP Jr, Velotta JB. Trends in Smoking-Specific Lung Cancer Incidence Rates Within a US Integrated Health System, 2007-2018. *Chest.* 2023 Sep;164(3):785-795. doi: 10.1016/j.chest.2023.03.016. Epub 2023 Mar 17. PMID: 36934804.

Mal Heme

1. Yavorkovsky LL. The role of staging in multiple myeloma. *Expert Rev Hematol.* 2023 Jul-Dec;16(12):933-942. doi: 10.1080/17474086.2023.2277876. Epub 2023 Dec 18. PMID: 37902242.

Sarcoma

1. Pan M, Zhou MY, Jiang C, Zhang Z, Bui NQ, Bien J, Siy A, Achacoso N, Solorzano AV, Tse P, Chung E, Thomas S, Habel LA, Ganjoo KN. Sex-dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma. *Clin Cancer Res.* 2024 Jan 17;30(2):413-419. doi: 10.1158/1078-0432.CCR-23-1990. PMID: 37831066; PMCID: PMC10792361.

Survivorship

1. Hinkle J, Wiener L, Altschuler A, Brock KE, Casperson M, Chao CR, Fisher L, Kushi LH, Lakin JR, Lefebvre A, Schwartz CM, Shalman DM, Wall CB, Mack JW. What Constitutes Quality of Life? Perspectives of Adolescents and Young Adults With Advanced Cancer. *J Natl Compr Canc Netw.* 2023 Dec;21(12):1243-1250. doi: 10.6004/jnccn.2023.7067. PMID: 38081124.

2. Mack JW, Cernik C, Uno H, Laurent CA, Fisher L, Xu L, Munneke J, Cannizzaro N, Casperson M, Schwartz CM, Lakin JR, Cooper RM, Altschuler A, Wiener L, Chao CR, Kushi L. Quality of End-of-Life Care Among Adolescents and Young Adults With Cancer. *J Clin Oncol*. 2024 Feb 20;42(6):621-629. doi: 10.1200/JCO.23.01272. Epub 2023 Oct 27. PMID: 37890132.
3. Mack JW, Cernik C, Uno H, Xu L, Laurent CA, Fisher L, Cannizzaro N, Munneke J, Cooper RM, Lakin JR, Schwartz CM, Casperson M, Altschuler A, Wiener L, Kushi L, Chao CR. Discussions About Goals of Care and Advance Care Planning Among Adolescents and Young Adults With Cancer Approaching the End of Life. *J Clin Oncol*. 2023 Oct 20;41(30):4739-4746. doi: 10.1200/JCO.23.00641. Epub 2023 Aug 25. PMID: 37625111; PMCID: PMC10602508.
4. Mack JW, Fisher L, Khalaj A, Altschuler A, Chao CR, Kushi LH, Casperson M, Lakin JR, Lefebvre A, Schwartz CM, Shalman DM, Wall CB, Wiener L. Quality Indicators for Adolescents and Young Adults With Advanced Cancer: A Modified Delphi Process With Patients, Family Members, and Clinicians. *J Pain Symptom Manage*. 2023 Jul;66(1):54-61. doi: 10.1016/j.jpainsymman.2023.03.005. Epub 2023 Mar 17. PMID: 36933749; PMCID: PMC10330073.
5. Mastropolo R, Altschuler A, Brock KE, Casperson M, Chao CR, Fisher L, Greenzang KA, Kushi LH, Lakin JR, Lefebvre A, Schwartz CM, Shalman DM, Wall CB, Wiener L, Mack JW. Patient, Caregiver, and Clinician Perspectives on Core Components of Therapeutic Alliance for Adolescents and Young Adults With Advanced Cancer: A Qualitative Study. *JAMA Netw Open*. 2023 Aug 1;6(8):e2328153. doi: 10.1001/jamanetworkopen.2023.28153. PMID: 37556137; PMCID: PMC10413170.

Palliative Care

2. Aller A, Hauser K, Pedell L, Martinez F, Lin A. Time is of the Essence: Why Goals-of-Care Conversations and Prognosis Documentation Matters in Advanced Cancer Patients in an Integrated Health System. *Am J Hosp Palliat Care*. 2023 Aug 18;10499091231188715. doi: 10.1177/10499091231188715. Epub ahead of print. PMID: 37592901. Aller A, Shirazi A, Pedell L, Altschuler A, Hauser K, Cheslock M, Wei J, Duffens A, Whitehead H, Lim P, Katzel J, Martinez F, Lin A, Aller S, Aller C, Jones T, Yen SM, Liu R. What Matters Most: The Documented Goals, Values and Motivators of Advanced Cancer Patients. *Am J Hosp Palliat Care*. 2023 Dec 19;10499091231223144. doi: 10.1177/10499091231223144. Epub ahead of print. PMID: 38112439.

Radiation oncology

7. Tang A, Dzubnar JM, Kelly JF, Banks KC, Phillips JL, Cureton EA, Svahn JD, Mai V, Lyon LL, Thomas ES, Shim VC. Intraoperative Radiation Therapy: A Large Integrated Health Care System's Approach and Outcomes. *Perm J*. 2023 Mar 15;27(1):45-55. doi: 10.7812/TPP/22.122. Epub 2023 Mar 6. PMID: 36872871; PMCID: PMC10013716.
8. Tchelebi LT, Winter KA, Abrams RA, Safran HP, Regine WF, McNulty S, Wu A, Du KL, Seaward SA, Bian SX, Aljumaily R, Shivnani A, Knoble JL, Crocenzi TS, DiPetrillo TA, Roof KS, Crane CH, Goodman KA. Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. *Int J Radiat Oncol Biol Phys*. 2024 Jan 1;118(1):107-114. doi: 10.1016/j.ijrobp.2023.08.014. Epub 2023 Aug 19. PMID: 37598723; PMCID: PMC10843017.

Technology

9. Oakley-Girvan I, Yunis R, Fonda SJ, Longmire M, Veuthey TL, Shieh J, Aghaee S, Kubo A, Davis SW, Liu R, Neeman E. Correlation Between Remote Symptom Reporting by Caregivers and Adverse Clinical

Outcomes: Mixed Methods Study. J Med Internet Res. 2023 Nov 21;25:e49100. doi: 10.2196/49100.
Erratum in: J Med Internet Res. 2024 Jan 30;26:e56368. PMID: 37988151; PMCID: PMC10698661.

10. Oakley-Girvan I, Yunis R, Fonda SJ, Neeman E, Liu R, Aghaee S, Ramsey ME, Kubo A, Davis SW. Usability evaluation of mobile phone technologies for capturing cancer patient-reported outcomes and physical functions. Digit Health. 2023 Jul 10;9:20552076231186515. doi: 10.1177/20552076231186515. PMID: 37456127; PMCID: PMC10338665.
11. Oakley-Girvan I, Yunis R, Fonda SJ, Neeman E, Liu R, Aghaee S, Ramsey ME, Kubo A, Davis SW. A novel smartphone application for the informal caregivers of cancer patients: Usability study. PLOS Digit Health. 2023 Mar 3;2(3):e0000173. doi: 10.1371/journal.pdig.0000173. PMID: 36867639; PMCID: PMC9983832.